Cannabis Continues to Garner Attention with the Rapid Expansion of CBD Products

NEW YORK, April 1, 2019 /PRNewswire/ -- Cannabis has become one of the most controversial topics on many countries' political agendas. Cannabis is still internationally illegal under regulatory statutes, but clinical trials and research have led countries to explore opportunities within the medical cannabis market. However, the recreational market is still widely being heavily enforced. Nonetheless, certain regions have moved to decriminalize, or even fully legalize, recreational cannabis use. Unlike marijuana, hemp's main component is CBD. While THC provides psychoactive effects to consumers, CBD does not induce psychoactive effects, but provide a therapeutic and relaxing effect akin to that of THC. Furthermore, because CBD does not provide any psychoactive effects, many countries have allowed personal use of the CBD as long as it contains less than 0.3% THC. According to data compiled by Hemp Business Journal, a division of New Frontier Data, the total sales for the U.S. hemp industry totaled USD 820 Million and is expected to grow to reach USD 1.9 Billion by 2022. Additionally, the market is projected to grow at a CAGR of 14.4% throughout the forecast period from 2018 to 2022. Overall, the industry is expected to be driven by increasing sales in the hemp-derived CBD and industrial application segments. Chineseinvestors.com Inc. CIIX, Tilray, Inc. TLRY, Canopy Growth Corporation CGC WEED, Cronos Group Inc. CRON CRON, Aphria Inc. APHA APHA

In 2017, the hemp-derived CBD product segment delivered USD 190 Million in sales, accounting for 23% of the overall market. The hemp food segment, which delivered USD 137 Million in sales, accounted for 17% of the hemp market that same year. By 2022, the food segment is expected to reach USD 212 Million as the segment is seeing major investments, primarily by large beverage corporations looking to enter into the cannabis-infused beverage industry. Many are looking to use cannabidiol, or CBD, to create therapeutic non-alcoholic drinks for consumers. However, CBD still remains popular among consumers in forms of capsules, oils, and flower itself. While the beverage industry is growing rapidly, other forms of CBD-based products are also seeing large growth. "The fact that a consumer-cannabis product has captured the attention of so many folks—from customers on the street to executives in the boardroom—reveals something far more lasting than whatever may come from this beverage product, even if it never launches," said Ben Curren, Chief Executive Officer and Founder of Green Bits. "What it reveals is that now, you and I and millions of people can picture this: the substance that once was considered the nation's most deadly, the very banner of America's war on drugs, might someday soon be "Brought to You By Coke," and not just as a social lubricant but as a sports recovery product applicable to an even wider audience."

Chineseinvestors.com Inc. CIIX just announced breaking CBD news this morning that, "that its wholly owned foreign enterprise , CBD Biotechnology Co. Ltd. ("CBD Biotech"), will participate in the 29th Vietnam International Trade Fair (Vietnam Expo) at the Hanoi International Exhibition Center (ICE) being held on April 10-13, 2019 in Hanoi.

As a featured exhibitor at the Vietnam Expo, CBD Biotech will introduce the new concept of "hemp plant extracting" and cosmetics. CBD Biotech will exhibit its self-branded hemp-infused skincare line as well as its hemp wine. CBD Biotech is one of the first companies to offer skincare products infused with hemp oil and hemp leaf extract in China. Focused on building new markets for industrial hemp products in throughout Asia, this expo will allow CBD Biotech to explore possible partnership opportunities for the Vietnamese market.

"The Vietnam Expo continues to be an important business destination to build bridges for trade promotion, foreign relations, facilitating commerce and attracting trade between Vietnamese and foreign enterprises," said Ms. Summer Yun, CEO of CBD Biotechnology Co. Ltd. "A pioneer in the Chinese market for hemp-infused skincare products and a Chinese originator of "hemp plant extracting" in combination with skincare, CBD Biotech's participation in this year's Vietnam Expo will give our brand the exposure needed to become an influencer within the Asian market. We anticipate creating lucrative export opportunities and exploring possible expansion to more Southeast Asian countries and members of ASEAN."

The Vietnam Expo, one of Vietnam's largest, most influential international exhibitions,

is hosted by the Ministry of Industry and Trade of Vietnam. This year the event will showcase 760 companies with over 1,000 international booths, with 35% of the companies being foreign and 65% Vietnam-based. The event provides foreign exhibitors the opportunity to educate Vietnamese business professionals regarding global trends and provides attendees the opportunity to purchase new products and learn about new technologies and investment opportunities.

CBD Biotech's current line of skincare products features the Popular Series which includes hemp peptide concentrate liquid, aqua bio-magnetic mask and hemp hyaluronic acid, the Live Oxygen Series which includes oxygen cleansing foam, oxygenated water and live oxygen cream, the Plant Series which includes Huanyan tone-up cream, aqua double moisturizer and peptide mineral essence, and the New Products Series which includes hemp eye pads, horse oil soap and hemp eye cream.

About ChineseInvestors.com - Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products. For more information, visit ChineseInvestors.com."

Tilray, Inc. TLRY is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents. Tilray, Inc. recently announced that it had entered into a definitive agreement, pursuant to which Tilray will acquire all of the issued and outstanding securities of FHF Holdings Ltd. from Compass Group Diversified Holdings, LLC CODI and other shareholders of Manitoba Harvest. Under the terms of the Agreement, Tilray will acquire Manitoba Harvest on a cash and debt-free basis, for an aggregate purchase price, including cash and class 2 Common Stock in the capital of Tilray, of up to CAD 19 Million pending the achievement of certain milestones after the closing of the Transaction. Together, Tilray and Manitoba Harvest plan to grow both companies' revenue while bringing nutritious hemp foods and supplements to more households across the U.S. and Canada. The acquisition will expand Tilray's product portfolio into the natural foods category and bring Manitoba Harvest expertise in working with cannabinoids, including cannabidiol (CBD). By leveraging Manitoba Harvest's established distribution network, Tilray plans to accelerate its expansion into the U.S. and Canadian markets, where legal, for CBD products. Manitoba Harvest also brings to Tilray an experienced team and manufacturing capabilities, including the addition of two high quality BRC AA+ certified manufacturing facilities as well as significant sales and distribution capabilities. "Tilray's acquisition of Manitoba Harvest is a milestone for the cannabis industry. It builds on the strategic partnerships we have formed with consumer brand industry leaders and demonstrates our track record of disrupting the global pharmaceutical, alcohol, CPG, and functional food and beverage categories," said Brendan Kennedy, Tilray President and Chief Executive Officer. "We're excited to work with Manitoba Harvest to develop and distribute a diverse portfolio of branded hemp-derived CBD food and wellness products in the U.S. and Canada."

Canopy Growth Corporation CGC WEED is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth Corporation and Sequential Brands Group, Inc. SQBG recently announced that Martha Stewart had joined the Company in an advisory role to assist with developing and positioning a broad new line of product offerings across multiple categories. With decades of success in publishing, broadcasting, online and merchandising, Martha Stewart has firmly cemented herself as one of the most well-respected businesswomen in the United States. Along with a deep understanding of what consumers in the United States and around the world want, Martha has been one of the most vocal advocates for animals, championing the health and wellness of pets and farm animals alike. With several clinical trials underway, Canopy Growth will be leaning on Martha's vast knowledge of consumer products while exploring the effectiveness of CBD and other cannabinoids as they relate to improving the lives of both humans and animals. As previously reported in January 2019, Canopy Growth has developed diverse product offerings specific to hemp-derived CBD and the Company looks forward to working closely with Martha Stewart as they further develop and introduce these products to market in the future. Canopy Growth previously reported that it will invest between USD 100 Million and USD 150 Million in a hemp industrial park in New York State with an intended purpose of being the Company's first hemp facility in the United States. "As soon as you hear the name Martha, you know exactly who we're talking about," shared Canopy Growth Chairman and co-Chief Executive Officer , Bruce Linton. "Martha is one of a kind and I am so excited to be able to work alongside this icon to sharpen our CBD product offerings across categories from human to animal."

Cronos Group Inc. CRON CRON is a globally diversified and vertically integrated cannabis company with a presence across four continents. Recently, Cronos Group Inc. and Ginkgo Bioworks Inc., the organism company, announced a landmark partnership to produce cultured cannabinoids. Using its platform technology for organism design and development, Ginkgo will complement Cronos Group's technologies for producing a full spectrum of cannabinoids. As part of this unprecedented deal, Cronos Group has agreed to issue a specific number of common shares in tranches subject to Ginkgo's achievement of certain production milestones. As two of the leading companies in their respective industries, Cronos Group and Ginkgo believe that they are best-suited to unlock the potential of innovation in the cannabis industry. Cronos Group brings a deep understanding of the plant's biological structure and function, while Ginkgo brings 10 years of experience designing microorganisms for the production of cultured products across pharmaceuticals, agriculture, flavors, fragrances, and more. "Cronos Group is building the world's most innovative cannabinoid platform," said Mike Gorenstein, Chief Executive Officer of Cronos Group. "The potential uses of cannabinoids are vast, but the key to successfully bringing cannabinoid-based products to market is in creating reliable, consistent, and scalable production of a full spectrum of cannabinoids, not just THC and CBD. We are thrilled to partner with Ginkgo; their biological engineering capabilities and disruptive technology platform are unrivaled. Together we can revolutionize the cannabis industry."

Aphria Inc. APHA APHA is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Aphria Inc. and Rapid Dose Therapeutics Inc. DOSE recently announced that they have expanded the scope of their previously announced agreement expanding the territory where Aphria has been granted exclusive preferred rights to license, manufacture, distribute and sell RDT's QuickStrip™ innovative, proprietary delivery technology for the cannabis market to Germany. RDT's proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral fast-dissolving drug delivery system that offers a smoke-free choice to consumers. Aphria expects to produce and distribute CBD-only Quickstrips™ in Germany by Spring 2019. As part of the Agreement, Aphria maintains the option to add future international markets as the opportunity in those markets evolve. "Germany is one of the most sought-after cannabis markets today, and Aphria continues to take a comprehensive approach to ensure a leading presence in the country as the opportunity evolves," said Jakob Ripshtein, President of Aphria. "Aphria is committed to bringing advanced products and innovations to cannabis markets around the world, and this agreement with RDT will enable us to bring QuickStrip™ technology to the German market and offer a unique nutraceutical product that delivers a consistent dosage."

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Chineseinvestors.com Inc. financial and corporate news dissemination, FinancialBuzz.com expects to be compensated three thousand five hundred dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: www.FinancialBuzz.com